Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A randomized, placebo-controlled, double-blind clinical trial of effect of allopurinol or febuxostat to prevent contrast induced acute kidney injury (CI-AKI)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez
• Collaborators: Armando Vázquez Rangel; Salvador López Gil
• Treatments: Allopurinol; Febuxostat

Criteria

Inclusion Criteria:

• Age 18 years and older who are scheduled to coronary intervention

• Patients with Mehran score > 5 or modified Mehran score >2 even glomerular filtration rate > 60 ml/min (high risk patients)

• Glomerular Filtration Rate < 60 ml/min

• All the patients provided written informed consent for the procedures and the test drug

Exclusion Criteria:

• Patients with shorter hospital stay (<48 hours)

• Patients under treatment with allopurinol of febuxostat

• Patients on renal replacement therapy

• Known allergy to allopurinol or febuxostat